Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Davis v. Boston Scientific Corp.

United States District Court, M.D. Florida, Fort Myers Division

May 11, 2018

FELICIA DAVIS, Plaintiff,
v.
BOSTON SCIENTIFIC CORPORATION, Defendant.

          OPINION AND ORDER [1]

          SHERI POLSTER CHAPPELL UNITED STATES DISTRICT JUDGE.

         This matter comes before the Court on Defendant Boston Scientific Corporation's (“Boston Scientific”) Motion to Dismiss (Doc. 21) and Plaintiff Felicia Davis' (“Davis”) Response in Opposition (Doc. 33). The matter is ripe for review.

         INTRODUCTION

         This is a product liability suit about Boston Scientific's permanent inferior vena cava filter (the “Greenfield Filter”). The Greenfield Filter was created to prevent pulmonary embolisms (Doc. 20 at ¶¶ 1, 29), which occur when a blood clot travels through blood vessels like the inferior vena cava to block one of the pulmonary arteries in the lungs. (Doc. 20 at ¶ 20). When clots form in deep leg veins, this condition is called deep vein thrombosis. (Doc. 20 at ¶ 20). Patients at risk of deep vein thrombosis or pulmonary embolisms are often treated with permanent or retrievable inferior vena cava filters, such as the Greenfield Filter, which trap and filter blood clots. (Doc. 20 at ¶¶ 23, 33, 36).

         Davis alleges that studies show the beneficial effects of implanting permanent inferior vena cava filters are offset by recurrent deep vein thrombosis symptoms. (Doc. 20 at ¶ 35). She further alleges that long-term implantation of inferior vena cava filters can cause subsequent pulmonary embolisms. (Doc. 20 at ¶ 29). Because of these factors, medical device manufacturers have developed retrievable inferior vena cava filters. (Doc. 20 at ¶¶ 35-36). In 2010, the United States Food and Drug Administration warned against implanting inferior vena cava filters for extended periods of time due to their potential to cause health complications. (Doc. 20 at ¶ 40). It released another warning in 2014. (Doc. 20 at ¶ 42). Despite these notifications, Davis alleges Boston Scientific continued to market the Greenfield Filter for long-term use. (Doc. 20 at ¶ 46).

         BACKGROUND

         In September 2005, Davis suffered a pulmonary embolism. (Doc. 20 at 24). Based on the advice of an unnamed entity, she agreed to have the Greenfield Filter implanted in her right common femoral vein. (Doc. 20 at ¶¶ 25-26). A decade later, she was hospitalized for chest pain and diagnosed with bilateral segmental pulmonary emboli. (Doc. 20 at ¶ 28). Almost two years after that, she was hospitalized again and diagnosed with deep vein thrombosis. (Doc. 20 at ¶ 30).

         Davis then sued Boston Scientific in state court. (Doc. 2). After the case was removed (Doc. 1), the Complaint was dismissed as a shotgun pleading. (Doc. 19). Davis filed an Amended Complaint, which deleted paragraphs that had previously incorporated every preceding allegation and added nineteen pages of additional allegations. (Doc. 20). The Amended Complaint alleges the Greenfield Filter was defectively designed and manufactured. (Doc. 20 at ¶ 59). It further claims the Greenfield Filter was inadequately tested and had inadequate warnings, instructions, and labeling. (Doc. 20 at ¶ 59). Based on these allegations, Davis claims Boston Scientific is liable for: negligence (Count I), strict liability design defect (Count II), strict liability manufacturing defect (Count III), strict liability failure to warn (Count IV), breach of express warranty (Count V), breach of implied warranty of merchantability (Count VI), breach of implied warranty of fitness (Count VII), fraudulent misrepresentation (Count VIII), fraudulent concealment (Count IX), negligent misrepresentation (Count X), and violations of the Florida Deceptive and Unfair Trade Practices Act (“FDUTPA”) (Count XI). (Doc. 20 at ¶¶ 72-336). Davis also seeks punitive damages. (Doc. 20 at ¶¶ 337-339). Now, Boston Scientific moves to dismiss. (Doc. 21).

         LEGAL STANDARD

         Under Federal Rule of Civil Procedure 8(a)(2), a pleading must contain a short and plain statement of a claim showing the pleader is entitled to relief. The Rule's purpose is to “give the defendant fair notice of what the claim is and the grounds upon which it rests.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (internal punctuation omitted).

         Fraud allegations are subject to heightened pleading standards under Federal Rule of Civil Procedure 9(b), which requires a party to “state with particularity the circumstances constituting fraud.” This means “a plaintiff must plead facts as to time, place, and substance of the defendant's alleged fraud, specifically the details of the defendant's allegedly fraudulent acts, when they occurred, and who engaged in them.” U.S. ex rel. Atkins v. McInteer, 470 F.3d 1350, 1357 (11th Cir. 2006) (internal quotations omitted). Stated differently, “[t]his means who, what, when, where, and how: the first paragraph of any newspaper story.” Garfield v. NDC Health Corp., 466 F.3d 1255, 1262 (11th Cir. 2006). But “[m]alice, intent, knowledge, and other conditions of a person's mind may be alleged generally.” Brooks v. Blue Cross & Blue Shield of Fla., Inc., 116 F.3d 1364, 1371 (11th Cir. 1997).These standards serve “an important purpose in fraud actions by alerting defendants to the precise misconduct with which they are charged and protecting defendants against spurious charges of immoral and fraudulent behavior.” Id. at 1370-71 (internal quotations omitted).

         Under Federal Rule of Civil Procedure 12(b)(6), a court may dismiss a pleading for failure to state a claim upon which relief can be granted. This decision hinges on the Twombly-Iqbal plausibility standard, which requires a plaintiff to allege sufficient facts “to raise a reasonable expectation that discovery will reveal evidence” to support a claim. Twombly, 550 U.S. at 556; see also Randall v. Scott, 610 F.3d 701, 708 n.2 (11th Cir. 2010). At this stage, the Court must accept all factual allegations in a complaint as true and take them in the light most favorable to the plaintiff. Pielage v. McConnell, 516 F.3d 1282, 1284 (11th Cir. 2008). But acceptance is limited to well-pleaded factual allegations. La Grasta v. First Union Sec., Inc., 358 F.3d 840, 845 (11th Cir. 2004). A “the-defendant-unlawfully harmed me accusation” is insufficient. Iqbal, 556 U.S. at 677. “Nor does a complaint suffice if it tenders naked assertions devoid of further factual enhancement.” Id. (internal quotations omitted).

         DISCUSSION

         Boston Scientific's Motion to Dismiss is multifaceted. It argues the Amended Complaint: (1) is an impermissible shotgun pleading; (2) is pled improvidently or insufficiently; and (3) fails to adequately allege punitive damages. Davis opposes. The Court will address each argument in turn.

         A. Shotgun Pleading

         Boston Scientific argues the Amended Complaint should be dismissed as a shotgun pleading because the grounds for each claim cannot be discerned. This argument fails. The Eleventh Circuit has defined only four types of shotgun pleadings:

The most common type-by a long shot-is a complaint containing multiple counts where each count adopts the allegations of all preceding counts, causing each successive count to carry all that came before and the last count to be a combination of the entire complaint. The next most common type, at least as far as our published opinions on the subject reflect, is a complaint that does not commit the mortal sin of re-alleging all preceding counts but is guilty of the venial sin of being replete with conclusory, vague, and immaterial facts not obviously connected to any particular cause of action. The third type of shotgun pleading is one that commits the sin of not separating into a different count each cause of action or claim for relief. Fourth, and finally, there is the relatively rare sin of asserting multiple claims against multiple defendants without specifying which of the defendants are responsible for which acts or omissions, or which of the defendants the claim is brought against. The unifying characteristic of all types of shotgun pleadings is that they fail to one degree or another, and in one way or another, to give the defendants adequate notice of the claims against them and the grounds upon which each claim rests.”

Weiland v. Palm Beach Cty. Sheriff's Office, 792 F.3d 1313, 1321-23 (11th Cir. 2015).

         Here, the Amended Complaint differs from the original because it no longer incorporates each preceding allegation into each count. Still, Boston Scientific argues it remains a shotgun pleading because Davis' addition of nineteen pages of allegations to the text of the original Complaint makes it difficult to understand the grounds for each claim. But that argument does not fall within one of the Eleventh Circuit's four shotgun pleading categories. Instead, it goes to Rule 8(a)(2)'s requirement for a “short and plain statement.” Fed.R.Civ.P. 8(a)(2). Under that framework, “so long as it is minimally sufficient to put a defendant on notice of the claims against him[, ] [a complaint] will not fail for mere surplusage.” Bailey v. Janssen Pharmaceutica, Inc., 288 Fed.Appx. 597, 603 (11th Cir. 2008). Though the Amended Complaint contains surplusage, that alone does not preclude Boston Scientific from understanding the claims lodged against it. The Amended Complaint does not fail as a shotgun pleading or under Rule 8(a)(2).

         B. Negligence

         Count I alleges Boston Scientific is liable for negligence. The elements of a negligence claim are “(1) a legal duty owed by defendant to plaintiff, (2) breach of that duty by defendant, (3) injury to plaintiff legally caused by defendant's breach, and (4) damages as a result of that injury.” Estate of Rotell ex rel. Rotell v. Kuehnle, 38 So.3d 783, 788 (Fla. 2d DCA 2010). Boston ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.